Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05541328 · ClinicalTrials.gov registry record
Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 169
- Enrollment target
NCT05541328 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 169 participants.
The verdict
NCT05541328 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 169 participants
- Enrollment target
Study Summary
This is a non-interventional, retrospective cohort study using the Flatiron Health Research Database (FHRD) and data from the single-arm phase II JULIET clinical trial (NCT02445248).
Interventions
- OTHER Tisagenlecleucel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2020-02-03 |
| Est. Completion | 2021-02-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05541328
The ClinicalTrials.gov registry entry for NCT05541328 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tisagenlecleucel is the first listed.
NCT05541328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05541328 about?
NCT05541328 is a clinical study titled "Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel". This is a non-interventional, retrospective cohort study using the Flatiron Health Research Database (FHRD) and data from the single-arm phase II JULIET clinical trial (NCT02445248).
What is the current status of trial NCT05541328?
This trial is currently completed. The enrollment target is 169 participants. The study started on 2020-02-03. Estimated completion is 2021-02-05.
What interventions are being tested in trial NCT05541328?
The interventions under investigation include: Tisagenlecleucel (OTHER).
Who is sponsoring clinical trial NCT05541328?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.